Securian Asset Management Inc increased its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 1.0% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 170,516 shares of the biopharmaceutical company’s stock after acquiring an additional 1,661 shares during the period. Securian Asset Management Inc’s holdings in Bristol-Myers Squibb were worth $7,733,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. James Investment Research Inc. grew its position in shares of Bristol-Myers Squibb by 36.5% in the first quarter. James Investment Research Inc. now owns 819 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 219 shares during the last quarter. Lowe Brockenbrough & Co. Inc. grew its position in shares of Bristol-Myers Squibb by 0.5% in the first quarter. Lowe Brockenbrough & Co. Inc. now owns 43,384 shares of the biopharmaceutical company’s stock valued at $2,070,000 after purchasing an additional 220 shares during the last quarter. Squar Milner Financial Services LLC grew its position in shares of Bristol-Myers Squibb by 5.6% in the first quarter. Squar Milner Financial Services LLC now owns 4,209 shares of the biopharmaceutical company’s stock valued at $200,000 after purchasing an additional 223 shares during the last quarter. Clear Harbor Asset Management LLC grew its position in shares of Bristol-Myers Squibb by 2.4% in the first quarter. Clear Harbor Asset Management LLC now owns 9,637 shares of the biopharmaceutical company’s stock valued at $460,000 after purchasing an additional 229 shares during the last quarter. Finally, Dynamic Advisor Solutions LLC grew its position in shares of Bristol-Myers Squibb by 1.0% in the first quarter. Dynamic Advisor Solutions LLC now owns 22,750 shares of the biopharmaceutical company’s stock valued at $1,085,000 after purchasing an additional 235 shares during the last quarter. Institutional investors and hedge funds own 80.11% of the company’s stock.

In other news, Director Robert J. Bertolini purchased 11,000 shares of the company’s stock in a transaction dated Wednesday, July 31st. The stock was bought at an average cost of $44.72 per share, for a total transaction of $491,920.00. Following the purchase, the director now owns 11,397 shares of the company’s stock, valued at $509,673.84. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.13% of the company’s stock.

Several equities analysts have recently commented on BMY shares. JPMorgan Chase & Co. started coverage on Bristol-Myers Squibb in a research report on Friday, May 3rd. They issued an “overweight” rating and a $62.00 target price on the stock. Goldman Sachs Group started coverage on Bristol-Myers Squibb in a research report on Tuesday, May 28th. They issued a “buy” rating and a $54.00 target price on the stock. Barclays raised Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $53.00 to $55.00 in a research report on Friday, May 3rd. Atlantic Securities raised Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 target price on the stock in a research report on Wednesday, August 14th. Finally, ValuEngine downgraded Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a research report on Tuesday, July 2nd. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $55.88.

NYSE:BMY traded up $0.03 during trading hours on Wednesday, reaching $47.67. 2,427,545 shares of the company were exchanged, compared to its average volume of 14,823,283. The company has a market capitalization of $76.85 billion, a P/E ratio of 11.98, a P/E/G ratio of 2.33 and a beta of 0.73. Bristol-Myers Squibb Co has a 1-year low of $42.48 and a 1-year high of $63.69. The company has a debt-to-equity ratio of 1.51, a current ratio of 3.88 and a quick ratio of 3.75. The business has a 50 day moving average of $45.47 and a 200 day moving average of $47.44.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, July 25th. The biopharmaceutical company reported $1.18 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.06 by $0.12. The business had revenue of $6.27 billion for the quarter, compared to the consensus estimate of $6.10 billion. Bristol-Myers Squibb had a return on equity of 47.63% and a net margin of 26.14%. The firm’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.01 earnings per share. As a group, equities research analysts anticipate that Bristol-Myers Squibb Co will post 4.26 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, August 1st. Shareholders of record on Friday, July 5th were issued a $0.41 dividend. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.44%. The ex-dividend date was Wednesday, July 3rd. Bristol-Myers Squibb’s dividend payout ratio is presently 41.21%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Featured Article: What is a Reverse Stock Split?

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.